Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protocol III: SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
NCT07053306Phase 1Recruiting
- Sponsor
- UT Health San Antonio
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by UT Health San Antonio. Primary endpoint: Ketone Body Turnover (ketogenesis) at 300 months. Started Apr 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07053306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053306.